Cofrancesco E, Colombi M, Gianese F, Cortellaro M
Centro per la Ricerca Clinico-Farmacologica e Terapeutica, Università degli Studi di Milano, Italy.
Thromb Res. 1990 Feb 1;57(3):405-14. doi: 10.1016/0049-3848(90)90256-c.
We evaluated the in vitro anticoagulant action of dermatan sulfate (DS) (aPTT, antiXa, anti-thrombin) and its effect on human platelet aggregation and beta TG/PF4 release induced by threshold doses of aggregating agents, compared with standard heparin (SH). In pooled plasma, DS prolonged aPTT much less than SH, had no measurable antiXa activity, showed an anti-thrombin activity similar to that shown by SH at a tenfold higher dilution. DS had no direct effect on human platelet aggregation and beta TG/PF4 release. Moreover it did not significantly affect platelet aggregation and release by ADP and collagen, whereas it completely inhibited platelet aggregation and beta TG/PF4 release by thrombin. These data in vitro confirm that thrombin inhibition induced by DS is accompanied by a far lesser aPTT prolongation compared to heparin, without any appreciable interference with platelet function.
我们评估了硫酸皮肤素（DS）的体外抗凝作用（活化部分凝血活酶时间、抗Xa活性、抗凝血酶活性）及其对由阈剂量聚集剂诱导的人血小板聚集和β-血小板球蛋白/血小板第4因子（βTG/PF4）释放的影响，并与标准肝素（SH）进行了比较。在混合血浆中，DS使活化部分凝血活酶时间延长的程度远小于SH，没有可测量的抗Xa活性，在高十倍的稀释度下显示出与SH相似的抗凝血酶活性。DS对人血小板聚集和βTG/PF4释放没有直接影响。此外，它对由二磷酸腺苷（ADP）和胶原诱导的血小板聚集和释放没有显著影响，而它完全抑制了由凝血酶诱导的血小板聚集和βTG/PF4释放。这些体外数据证实，与肝素相比，DS诱导的凝血酶抑制伴随着活化部分凝血活酶时间延长程度小得多，且对血小板功能没有任何明显干扰。
